The suspicion that opioid drugs for pain could encourage cancer growth began with a laboratory report from the University of Minnesota in 2002. Then at the University of Chicago, cancer patients in clinical trials of the opioid-blocker methylnaltrexone – a form of naltrexone developed to reverse opioid side effects such as itching & constipation without affecting pain relief – began living longer than expected.
Leave a Reply
You must be logged in to post a comment.